A BILL 
To preserve access to abortion medications. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Protecting Access to 
4
Medication Abortion Act’’. 
5
SEC. 2. MODIFICATION OF REMS. 
6
(a) IN GENERAL.—The Secretary of Health and 
7
Human Services (referred to in this section as the ‘‘Sec-
8
retary’’) shall require the responsible person involved to 
9
submit a proposal under subsection (g)(4)(A) of section 
10
505–1 of the Federal Food, Drug, and Cosmetic Act (21 
11
06:00 Jul 21, 2022
H8405
2 
•HR 8405 IH
U.S.C. 355–1) to modify the risk evaluation and mitiga-
1
tion strategy under such section that applies to 
2
mifepristone so that— 
3
(1) the in-person dispensing requirement is re-
4
moved from such risk evaluation and mitigation 
5
strategy; 
6
(2) patients may access prescriptions for such 
7
drug via telehealth; and 
8
(3) all pharmacies that are certified to dispense 
9
such drug are permitted to, at minimum, dispense 
10
and mail such drug to patients. 
11
(b) MODIFICATIONS.—Nothing in subsection (a) shall 
12
be construed to prevent the Secretary from approving a 
13
modification to the risk evaluation and mitigation strategy 
14
for mifepristone based on sound scientific evidence and in 
15
accordance with section 505–1(h) of the Federal Food, 
16
Drug, and Cosmetic Act (21 U.S.C. 355–1(h)). Any modi-
17
fications to such risk evaluation and mitigation strategy 
18
made after the proposal to modify required pursuant to 
19
subsection (a) shall be in accordance with the require-
20
ments under paragraphs (1), (2), and (3) of such sub-
21
section, unless the Secretary, based on sound scientific evi-
22
dence and in accordance with section 505–1 of such Act 
23
(21 U.S.C. 355–1), determines that a risk evaluation and 
24
06:00 Jul 21, 2022
H8405
3 
•HR 8405 IH
mitigation strategy for mifepristone is no longer nec-
1
essary. 
2
(c) CLARIFICATION.—Nothing in subsection (a) shall 
3
be construed to limit the authority of the Secretary to im-
4
pose the requirements described in paragraphs (1), (2), 
5
and (3) of such subsection to a risk evaluation and mitiga-
6
tion strategy under section 505–1 of the Federal Food, 
7
Drug, and Cosmetic Act (21 U.S.C. 355–1) for any drug 
8
other than mifepristone. 
9
(d) 
DEFINITION.—In 
this 
section, 
the 
term 
10
‘‘mifepristone’’ means mifepristone that is— 
11
(1) approved under subsection (c) or (j) of sec-
12
tion 505 of the Federal Food, Drug, and Cosmetic 
13
Act (21 U.S.C. 355); 
14
(2) indicated for medical abortion; and 
15
(3) subject to a risk evaluation and mitigation 
16
strategy under section 505–1 of the Federal Food, 
17
Drug, and Cosmetic Act (21 U.S.C. 355–1). 
18
Æ 
06:00 Jul 21, 2022
H8405
